Showing 4931-4940 of 8208 results for "".
- Study: Positive Safety and Tolerability Results for Ortho Dermatologics' Altreno for Acnehttps://practicaldermatology.com/news/study-positive-results-for-ortho-dermatologics-altrenos-safety-and-tolerability-for-acne/2457569/Ortho Dermatologics shared results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of Altreno (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topi
- Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-received-tentative-fda-approval-for-bryhali-for-plaque-psoriasis/2457575/The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion is a new potent to superpotent corticosteroid that contains 0.01 percent halobetasol propionate i
- Allergan's New Campaign Urges Consumers to Just Juvéderm Ithttps://practicaldermatology.com/news/allergans-new-campaign-urges-consumers-to-just-juvderm-it/2457581/Allergan plc is rolling out a new Juvéderm advertising campaign that aims to make this family of fillers a household name. Comprising a modernized logo, a bright, poppy color scheme, an edgy soundtrack and robust social media component, Juvéderm It is the first new adv
- Dermira's Qbrexa Cloth Now Available for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-qbrexa-cloth-now-available-for-primary-axillary-hyperhidrosis/2457582/Dermira, Inc.'s Qbrexa (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis. The new therapy is available in retail and community pharmacies nationwide. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was FDA approved to treat adul
- Ortho Dermatologics' Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ortho-dermatologics-psoriasis-drug-bryhali-performs-well-in-two-phase-3-trials/2457585/Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe plaque psoriasis, is effective and well-tolerated. Bryhali Lotion has a Prescription Drug
- LEO Science & Tech Hub and Epicore Biosystems to Explore Wearable Skin Sensors to Improve Dermatologic Treatment Regimenshttps://practicaldermatology.com/news/leo-science-tech-hub-and-epicore-biosystems-to-explore-wearable-skin-sensors-to-improve-dermatologic-treatment-regimens/2457583/LEO Science & Tech Hub has established a new partnership with Epicore Biosystems focused on exploring the use of a non-invasive, wearable sweat sensor to measure prognostic biomarkers in real time, monitor patient response and inform treatment decisions. The initial project will inc
- Seysara: Oral Antibiotic is First Approved for Dermatology in 40 Yearshttps://practicaldermatology.com/news/seysara-oral-antibiotic-is-first-approved-for-dermatology-in-40-years/2457584/Seysara (sarecycline), a new, first in class tetracycline-derived oral antibiotic, is now approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Almirall, which recently acquired Seysara from Allergan, plans to laun
- Research Identifies Disparities in Outpatient Dermatologic Carehttps://practicaldermatology.com/news/research-identifies-disparities-in-outpatient-dermatologic-care/2457592/The odds of a black or Hispanic patient visiting an outpatient dermatologist are about half that of a white patient with the same skin condition, according to a new study in JAMA Dermatology. Patie
- Almirall Finalizes Acquisition of Allergan US Medical Dermatology Portfoliohttps://practicaldermatology.com/news/almirall-finalizes-acquisition-of-allergan-us-medical-dermatology-portfolio/2457600/Almirall, S.A. finalized its acquisition of products from Allergan's Medical Dermatology unit in the US: Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), and Cordran Tape (flurandrenolide). In addition, sarecycline, a New Chemical Entity (NCE) currently under FDA review for appr
- XBiotech Adds Dr. Alice Gottlieb to its Scientific Advisory Boardhttps://practicaldermatology.com/news/xbiotech-adds-dr-alice-gottlieb-to-its-scientific-advisory-board/2457599/Alice Gottlieb, MD, PhD joined XBiotech Inc.'s Scientific Advisory Board (SAB). Dr. Alice Gottlieb is internationally recognized for her expertise and pioneering work in the development of biological therapies to treat skin diseases. Dr. Gottlieb has played key roles in the clinical eval